Navigation Links
Advanced Prenatal Therapeutics Appoints Dr. Nihar Nayak to its Scientific Advisory Board

LAGUNA HILLS, Calif., July 29, 2013 /PRNewswire/ -- Advanced Prenatal Therapeutics, Inc. (APT), a private company developing the first medical device specifically designed to treat preeclampsia, is happy to announce the appointment of its first scientific advisor: Nihar Nayak, PhD, DVM. Dr. Nayak brings to the table over 16 years of research experience and a passion for the development of novel products to treat preeclampsia.

Dr. Nayak is an Associate Professor of Obstetrics and Gynecology (Research) and the Director of Translational Research in the Division of Maternal Fetal Medicine at Stanford University School of Medicine. As a key scientific leader in the prenatal field with extensive expertise in translational research, Dr. Nayak will offer APT a valuable perspective on product development and study design.

"His prior work with sFlt-1 and his expertise in translational research make him exceptionally valuable as an advisor and research collaborator," explains Dr. James Smith, CEO and President of APT. "Dr. Nayak's affiliation with Stanford's world-class research and clinical environment provides us with extraordinary resources and opportunities to advance our product commercialization efforts."

One of Dr. Nayak's major research goals is to understand the uterine mechanisms that affect blood vessel development during preeclampsia and to facilitate the translation of cutting edge research into new therapies. "Preeclampsia, a leading cause of prematurity and maternal and fetal death, is a completely unmet medical need," explains Dr. Nayak. "Research and development using therapeutic targets like sFlt-1 and other circulating factors could open the door to much needed therapies for preeclampsia patients."

Dr. Nayak has received several research awards, including the Lalor Foundation postdoctoral fellowship, the Andrew Mellon Foundation Junior Investigator Award, and the NIH BIRCWH award. Recently, Dr. Nayak also received a Vision Grant from the Preeclampsia Foundation to study the role of placental proteins in preeclampsia with a focus on sFlt-1 and vascular endothelial growth factor VEGF, the biomarkers affected by APT's initial product development efforts.

About Advanced Prenatal Therapeutics, Inc. ( Advanced Prenatal Therapeutics, Inc.'s mission is to develop treatments for preeclampsia that will safely prolong pregnancy. To accomplish this goal, APT is developing a novel therapeutic device for preeclampsia that specifically removes disease-causing factors from the mother's blood. This press release may contain forward-looking statements. There can be no assurance that development efforts will succeed, or that the novel therapeutic products will receive regulatory clearance, or achieve commercial success.

Investor Relations:
Dan Thiel
Advanced Prenatal Therapeutics, Inc.

SOURCE Advanced Prenatal Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
2. Advanced Circulatory Selects Combat Medical Systems As Its Exclusive Sales Distributor for Military and Federal Market in US
3. WebPAX v8 - The fastest, most technologically advanced zero-footprint medical image viewer yet
4. New RCSA Certification Curriculum Uses Angio Mentor Simulators for Advanced Training
5. JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
6. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
7. Belrose Pharma Acquires Enzons Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies
8. New drug proving effective in attacking advanced prostate cancer
9. Ochsner Health System Improves Safety Through Advanced Medication Management Technology
10. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
11. New Air Products Microsite Features Advanced Liquid Nitrogen Solutions for the Chemical, Pharmaceutical, and Life Science Industries
Post Your Comments:
(Date:11/24/2015)... 2015  Thanks to a donor with a personal ... Center,s Sister Diane Grassilli Center for Women,s Health now ... San Francisco . Fred ... with a gift of $617,320 that allowed the Center ... Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... new market research report "Spine Biologics Market by Product Type ... Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), ... by MarketsandMarkets, the global market was valued at $1.90 Billion ... 2020, at a CAGR of 4.4% during the forecast period ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, ... evaluating the efficacy of its product and its disinfection protocol. This study is taking ... 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... 25, 2015 , ... Many people know of the common symptoms of low ... dry skin. But many people who find their cholesterol levels and weight are creeping ... thyroid, especially if they don’t have any of the other symptoms. , Thyroid hormone ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion ... in an early celebration of the early holiday shopping season. Starting Wednesday November ... (normally $33.95 ea). Black Friday promotional pricing is in addition to any automatic ...
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
Breaking Medicine News(10 mins):